Management of bleeding and emergency invasive procedures in patients on dabigatran: updated guidelines from the French Working Group on Perioperative Haemostasis (GIHP) - September 2016.

Date publication

mai 2018

Journal

Anaesthesia, critical care & pain medicine

Auteurs

Membres identifiés du Cancéropôle Est :
Pr NGUYEN Philippe

Tous les auteurs :
Albaladejo P, Pernod G, Godier A, de Maistre E, Rosencher N, Mas JL, Fontana P, Samama CM, Steib A, Schlumberger S, Marret E, Roullet S, Susen S, Madi-Jebara S, Nguyen P, Schved JF, Bonhomme F, Sié P

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/29729372

Résumé

In 2013, the GIHP published guidelines for the management of severe haemorrhages and emergency surgery. This update applies to patients treated with dabigatran, with a bleeding complication or undergoing an urgent invasive procedure. It includes how to handle the available specific antidote (idarucizumab), when to measure dabigatran plasmatic concentration, and when to use non-specific measures in these situations. It also includes guidelines on how to perform regional anaesthesia and analgesia procedures.

Mots clés

Antidote, Bleeding, Dabigatran, Dabigatran concentration, Emergency, Surgery

Référence

Anaesth Crit Care Pain Med. 2018 May 2;: